Myriad Genetics, Inc. (NASDAQ:MYGN) has been assigned an average recommendation of “Hold” from the thirteen ratings firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $26.40.

A number of analysts recently issued reports on MYGN shares. Cowen and Company reaffirmed a “hold” rating and issued a $25.00 target price on shares of Myriad Genetics in a research report on Friday, July 14th. Piper Jaffray Companies reissued a “hold” rating and set a $22.00 price target on shares of Myriad Genetics in a research report on Friday, July 14th. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Monday, July 17th. BidaskClub downgraded Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Finally, Barclays PLC reduced their price objective on Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating for the company in a report on Wednesday, August 9th.

Myriad Genetics (MYGN) opened at 34.86 on Friday. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $37.30. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of 109.28 and a beta of 0.28. The firm has a 50-day moving average price of $34.82 and a 200 day moving average price of $26.69.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.04. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The firm had revenue of $200.50 million for the quarter, compared to the consensus estimate of $193.71 million. During the same quarter last year, the business posted $0.36 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. On average, equities analysts forecast that Myriad Genetics will post $1.03 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/29/myriad-genetics-inc-mygn-receives-consensus-rating-of-hold-from-brokerages-2.html.

In other news, Director John T. Henderson sold 30,000 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $30.30, for a total transaction of $909,000.00. Following the transaction, the director now owns 52,524 shares of the company’s stock, valued at approximately $1,591,477.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Crossmark Global Holdings Inc. bought a new position in Myriad Genetics in the 3rd quarter valued at about $655,000. IFC Holdings Incorporated FL bought a new position in Myriad Genetics in the 3rd quarter valued at about $438,000. Parsec Financial Management Inc. bought a new position in Myriad Genetics in the 3rd quarter valued at about $1,174,000. Meeder Asset Management Inc. lifted its position in Myriad Genetics by 1,067.4% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock valued at $119,000 after acquiring an additional 3,010 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in Myriad Genetics by 97.2% in the 3rd quarter. Fisher Asset Management LLC now owns 120,312 shares of the company’s stock valued at $4,353,000 after acquiring an additional 59,301 shares in the last quarter.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.